Treatment of Slow-Growing Lymphoma (Follicular Lymphoma)

Initial Management

The European Society for Medical Oncology recommends watchful waiting for asymptomatic patients with advanced-stage, low tumor burden follicular lymphoma, while symptomatic or high tumor burden disease requires immunochemotherapy with obinutuzumab or rituximab combined with bendamustine or CHOP, followed by rituximab maintenance 1
For limited-stage disease with curative potential, radiotherapy at 24 Gy is the treatment of choice 1, 2
Involved field radiotherapy should be used for patients with documented contiguity of lymph nodes treatable in the same field 2
Stage II patients with high tumor burden or FLIPI >2 should receive chemoimmunotherapy instead 2
Asymptomatic, low tumor burden patients should be managed with a watch-and-wait approach, with treatment initiated only when symptoms develop, including B symptoms, hematopoietic impairment, bulky disease, vital organ compression, ascites or pleural effusion, or rapid lymphoma progression 1, 3
First-line therapy for symptomatic or high tumor burden disease should be obinutuzumab or rituximab combined with either bendamustine or CHOP 1, 3
Rituximab maintenance every 2 months for 2 years is recommended after immunochemotherapy 1, 3

A non-cross-resistant regimen is preferred for early relapse (<12-24 months) 1, 4
Rituximab should be added if previous antibody-containing regimen achieved >6-12 months duration of remission 1
In rituximab-refractory cases or remissions <6 months, obinutuzumab-bendamustine plus obinutuzumab maintenance is recommended 1, 4
Rituximab maintenance every 3 months for up to 2 years is recommended after relapse therapy 1, 3
High-dose chemotherapy with autologous stem cell transplant should be considered in patients with brief first remissions after rituximab-containing regimens 1, 4

In patients with positive hepatitis B serology, including occult carriers, prophylactic antiviral medication up to 2 years beyond last rituximab exposure is strongly recommended 1, 3
At suspected relapse or progression, obtain a new confirmatory biopsy 1, 4
PET-CT after completion of induction identifies patients with adverse prognosis, though therapeutic consequences remain undefined 1, 4
Structural imaging should be performed mid-treatment and after completion of chemotherapy 1, 4